瘦型与非瘦型代谢功能障碍相关脂肪性肝病肝纤维化遗传风险比较
该横断面研究纳入312例MASLD成人,按年龄性别匹配比较瘦型与非瘦型患者显著纤维化患病率及遗传风险评分(GRS)的影响。结果显示瘦型与非瘦型显著纤维化患病率相似(27.3% vs 31.1%,p=0.653),高GRS者纤维化患病率更高(36.5% vs 25.2%,p=0.043),且高GRS的瘦型与非瘦型患者纤维化患病率相似。拉丁美洲外部队列验证结果类似。
要点
- 瘦型与非瘦型MASLD患者显著纤维化患病率无显著差异。
- 高遗传风险评分(GRS)与显著纤维化患病率升高相关。
- 高GRS的瘦型与非瘦型患者纤维化风险相似。
核心结论
- 瘦型与非瘦型MASLD患者的显著纤维化患病率及遗传风险评分效应相似。
- 瘦型MASLD患者可能具有与超重和肥胖MASLD患者相当的纤维化风险。
研究设计与样本
- 研究为前瞻性入组MASLD成人的横断面分析,瘦型与非瘦型按年龄和性别匹配。
- 纤维化评估包括振动控制瞬时弹性成像、磁共振弹性成像和肝活检。
- 遗传风险评分(GRS)汇总PNPLA3和TM6SF2效应等位基因减去保护性HSD17B13基因型。
- 结果在外部拉丁美洲队列中验证。
主要发现
- 312例MASLD参与者平均年龄58.3±11.6岁,69.2%为女性。
- 瘦型44例(14.1%),超重90例(28.9%),I度肥胖90例(28.9%),II度及以上肥胖88例(28.1%)。
- 显著纤维化患病率瘦型为27.3%,非瘦型为31.1%(p=0.653)。
- 高GRS者显著纤维化患病率高于低GRS者(36.5% vs 25.2%,p=0.043)。
- 高GRS的瘦型与非瘦型患者显著纤维化患病率相似(31.3% vs 37.1%,p=0.645)。
临床怎么用
- 瘦型MASLD患者应被视为具有与超重/肥胖患者相当的显著纤维化风险。
- 遗传风险评分可能有助于识别高纤维化风险的MASLD患者,无论BMI类别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Previous studies have revealed conflicting results regarding liver fibrosis risk in lean metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to compare the risk of significant fibrosis in lean versus nonlean MASLD and identify fibrosis-associated factors in lean MASLD. METHODS: The study was a cross-sectional analysis of prospectively enrolled adults with MASLD. Individuals with lean MASLD were age- and sex-matched with nonlean MASLD. Fibrosis assessment included vibration-controlled transient elastography, magnetic resonance elastography and liver biopsy. A genetic risk score (GRS), summating the effect alleles of PNPLA3 and TM6SF2 minus the protective HSD17B13 genotype, was estimated to consider inherited genetic risk across BMI categories. Results were validated in an external Latin American cohort. RESULTS: The mean ( ± SD) age of 312 included participants with MASLD was 58.3 ± 11.6 years and 69.2% were female. 44 (14.1%) individuals were lean, 90 (28.9%) were overweight, 90 (28.9%) had class I obesity and 88 (28.1%) had class II or greater obesity. The prevalence of significant fibrosis was 27.3% in lean and 31.1% in nonlean (p = 0.653). Individuals with a high GRS had a higher prevalence of significant fibrosis compared to patients with low GRS (36.5% vs. 25.2%, p = 0.043) and the prevalence of significant fibrosis was similar in lean and nonlean patients with high GRS (31.3% vs. 37.1%, p = 0.645). The Latin American cohort exhibited similar results. CONCLUSIONS: The prevalence of significant fibrosis and the effect of GRS were similar in lean and nonlean MASLD, highlighting that lean MASLD patients may have a comparable risk to overweight and obese MASLD.
引用
- Tesfai K, Díaz LA, Arab JP, et al. Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Aliment Pharmacol Ther. 2025. PMID: 41147688. doi:10.1111/apt.70433
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。